Kremlin: Putin made no statements on participation in 2018 presidential electionRussian Politics & Diplomacy February 21, 13:15
Kremlin declines to comment on appointment of Trump’s new national security adviserRussian Politics & Diplomacy February 21, 13:09
Press review: Russia’s UN envoy dies in New York and Iran urges closer ties with MoscowPress Review February 21, 13:00
Peskov on Ukraine blocking UNSC statement on Russia's late envoy: 'May God judge them'Russian Politics & Diplomacy February 21, 12:59
President of Azerbaijan appoints his wife as first vice-presidentWorld February 21, 12:37
Ukrainian MP Savchenko renounces parliamentary immunityWorld February 21, 12:32
Lavrov voices hope for restoration of Russia-Sweden relationsRussian Politics & Diplomacy February 21, 12:21
Diplomats all over the world will remember Churkin as an outstanding professional — LavrovRussian Politics & Diplomacy February 21, 11:50
Ukraine stonewalls adoption of UNSC statement dedicated to Russia’s envoy ChurkinWorld February 21, 11:26
EINDHOVEN, Netherlands, Sept. 8, 2015 /PRNewswire/. As the number of trained pathologists decreases while the aging population and complexity of cancer is on the rise, Royal Philips (NYSE: PHG, AEX: PHIA) today announced the growing adoption of its Digital Pathology Solutions by health systems across the globe who are enhancing their operations. Through its IntelliSite Pathology Solution*, Philips enables health care organizations to reinvent the traditional histopathology workflow, enhance efficiency and productivity, and improve the confidence in making diagnosis.
Photo - http://photos.prnewswire.com/prnh/20150908/264234
Photo - http://photos.prnewswire.com/prnh/20150908/264235
Through examination of patient tissue samples, pathology plays a crucial role in the diagnosis, management and prevention of a variety of diseases, including cancer. As health care cost and quality pressures continue to mount, digital pathology can help improve the efficiency and quality of cancer diagnostics. Several high-volume and networked pathology institutions across the world have implemented the Philips digital pathology platform, which offers an integrated approach to improve workflows, enhance collaboration capabilities to speed up consults, unify patient data and enable a flexible growth path to get more information from tumor tissue.
"Modern pathology labs are coming under continued pressure to increase throughput and efficiency while improving quality," said Russell Granzow, General Manager of Philips Digital Pathology Solutions. "As the shift towards personalized medicine requires pathology data that guides the right therapy for the right patient at the right time, Philips is driving the evolution toward digitized workflows to ensure pathologists are empowered to meet industry demand."
Across the globe, leading institutions are leveraging Philips' experience in clinical digital transformation to help pathology laboratories make that next step in workflow improvement and accelerate knowledge sharing between care providers.
For further information, please contact:
Philips Digital Pathology Solutions
+31 6 10 610 417
Philips Group Communications
+31 6 1088 8824
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people's lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2014 sales of EUR 21.4 billion and employs approximately 108,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at www.philips.com/newscenter.
* Philips IntelliSite Pathology Solution is CE marked for primary diagnostics in the EU and Health Canada. In the U.S., Philips IntelliSite Pathology Solution is cleared by FDA for diagnostic use in the evaluation of HER2 expression in breast cancer and is offered for research use (RUO).